Differentiating the Effect of Medication and Illness on Brain Volume Reductions in First-Episode Psychosis: A Longitudinal, Randomized, Triple-blind, Placebo-controlled MRI Study
Authors:
- Sidhant ChopraSCSidhant Chopra
- Alex FornitoAFAlex Fornito
- Shona M. FranceySFShona M. Francey
- Brian O’donoghueBOBrian O’donoghue
- Vanessa CropleyVCVanessa Cropley
- Barnaby NelsonBNBarnaby Nelson
- Jessica GrahamJGJessica Graham
- Lara BaldwinLBLara Baldwin
- Steven TahtalianSTSteven Tahtalian
- Hok Pan YuenHYHok Pan Yuen
- Kelly AllottKAKelly Allott
- Mario Alvarez-JimenezMAMario Alvarez-Jimenez
Preprint
Abstract
Changes in brain volume are a common finding in Magnetic Resonance Imaging (MRI) studies of people with psychosis and numerous longitudinal studies suggest that volume deficits progress with illness duration. However, a major unresolved question concerns whether these changes are driven by the underlying illness or represent iatrogenic effects of antipsychotic medication. Here, we report MRI findings from a triple-blind randomised placebo-controlled study where 62 antipsychotic-naïve patients with first episode psychosis (FEP) received either an atypical antipsychotic or a placebo pill over a treatment period of 6 months. Both FEP groups received intensive psychosocial therapy. A healthy control group (n=27) was also recruited. Structural MRI scans were obtained at baseline, 3-months and 12- months. Our primary aim was to differentiate illness-related brain volume changes from medication-related changes within the first 3 months of treatment. We secondarily investigated long-term effects at the 12-month timepoint. From baseline to 3 months, we observed a significant group x time interaction in the pallidum (p < 0.05 FWE-corrected), such that patients receiving antipsychotic medication showed increased volume, patients on placebo showed decreased volume, and healthy controls showed no change. In patients, a greater increase in pallidal grey matter volume over 3 months was associated with a greater reduction in symptom severity. We additionally found preliminary evidence for illness- related volume reductions in prefrontal cortices at 12 months and medication-related volume reductions in cerebellum at both 3-months and 12-months. Our findings indicate that psychotic illness and antipsychotic exposure exert distinct and spatially distributed effects on brain volume. Our results align with prior work in suggesting that the therapeutic efficacy of antipsychotic medications may be primarily mediated through their effects on the basal ganglia.Keywords
All Related Versions
- Published version: Neuropsychopharmacology, 46 (8), 1494.
This publication has 45 references indexed in Scilit:
- The Myth of Schizophrenia as a Progressive Brain DiseaseSchizophrenia Bulletin, 2012
- Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate TreatmentSchizophrenia Research and Treatment, 2011
- Long-term Antipsychotic Treatment and Brain VolumesArchives of General Psychiatry, 2011
- Cortical Thickness Reduction in Individuals at Ultra-High-Risk for PsychosisSchizophrenia Bulletin, 2009
- The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common PathwaySchizophrenia Bulletin, 2009
- Mapping grey matter reductions in schizophrenia: An anatomical likelihood estimation analysis of voxel-based morphometry studiesSchizophrenia Research, 2009
- Effect of Chronic Antipsychotic Exposure on Astrocyte and Oligodendrocyte Numbers in Macaque MonkeysBiological Psychiatry, 2008
- A fast diffeomorphic image registration algorithmNeuroImage, 2007
- Globus pallidus volume is related to symptom severity in neuroleptic naive patients with schizophreniaSchizophrenia Research, 2005
- An MRI Study of Basal Ganglia Volumes in First-Episode Schizophrenia Patients Treated With RisperidoneAmerican Journal of Psychiatry, 2001